Print

AVEG 002B

A Phase I Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination with Soluble Recombinant Envelope Vaccine (VaxSyn)

Trial Details:

I Completed
National Institute of Allergy and Infectious Diseases (NIAID) March 28, 1991
HIVAC-1e,VaxSyn gp160 Vaccine (MicroGeneSys) Vaccinia Env gp160 B; Protein Env gp160 B LAI
HIVAC-1e Viral Vector - Pox
VaxSyn gp160 Vaccine (MicroGeneSys) Protein
USA 13
NCT00000631
http://clinicaltrials.gov/ct2/show/NCT00000631